This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years. The different research focusses are: * Identification of clinical parameters and patient characteristics / host-related factors in long-term survivors (Focus 1) * Identification of molecular tumor characteristics in long-term survivors (Focus 2) * Assessment of therapy-related parameters, including neuro-toxicity (Focus 3) * Immunological studies (Focus 4)
Study Type
OBSERVATIONAL
Enrollment
599
Dana-Farber Cancer Institute & Harvard Medical School
Boston, Massachusetts, United States
Universitaetsklinikum Wien - AKH uniklinieken
Vienna, Austria
Hopitaux Universitaires Bordet-Erasme
Brussels, Belgium
CHU Lyon - Hopital neurologique Pierre Wertheimer
Bron, France
CHRU de Lille
Lille, France
Hopitaux de Marseille - Hôpital de La Timone (APHM)
Marseille, France
Institut du Cancer de Montpellier
Montpellier, France
CHU de Nice - Hopital Pasteur
Nice, France
Hopitaux de Paris - Hopital Saint-Louis
Paris, France
Hopitaux de Paris - La Pitie Salpetriere
Paris, France
...and 17 more locations
Overall Survival
Time frame: 1 year from last patient in
Molecular profiling on FFPE samples
Profiling for cytosine-phosphate-guanosine (CpG) methylation patterns using the Illumina 850k bead array platform
Time frame: 1 year from last patient in
Molecular profiling on frozen samples
Samples will be subjected to whole exome sequencing
Time frame: 1 year from last patient in
Molecular profiling on frozen samples
Samples will be subjected to messenger ribonucleic acid (mRNA) sequencing
Time frame: 1 year from last patient in
Molecular profiling on frozen samples
Samples will be subjected to miRNA sequencing
Time frame: 1 year from last patient in
Molecular profiling on frozen samples
Samples will be subjected to microarray-based expression profiling
Time frame: 1 year from last patient in
Proteome profiling
Tumor cells will be microdissected from frozen sections and prepared for high-resolution mass spectrometry
Time frame: 1 year from last patient in
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.